MedImmune Ventures and CVF co-lead a $19m Series C into US-based medical device company Cerapedics.
Cerapedics, a developer of biologic bone grafts, has raised $19m in Series C funding. Anglo-Swedish drugs company AstraZeneca’s corporate venturing division, MedImmune Ventures and CVF, an affiliate of Henry Crown and Company, co-led the round. They were joined by return backers healthcare-dedicated investment firm OrbiMed Advisors and healthcare venture capital investment firm NGN Capital.
In conjunction with the financing, Sam Wu, managing director of MedImmune Ventures, has joined Cerapedic’s board.
Cerapedics previously raised $15m in 2009 a Series B from NGN…
